Discontinued — last reported Q3 '23
Complex GX and Biosimilars — Sales Revenue, Goods, Net
Viatris Complex GX and Biosimilars — Sales Revenue, Goods, Net increased by 25.3% to $174.40M in Q3 2023 compared to the prior quarter. Year-over-year, this metric declined by 45.5%, from $320.20M to $174.40M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful commercialization of high-barrier products and potential market share expansion in specialized therapeutic areas, while a decrease may signal increased competition or regulatory hurdles in the biosimilar space.
Detailed definition
This metric represents the net revenue generated from the sale of complex generic pharmaceuticals and biosimilar product...
Peer comparison
Peers in the generic and specialty pharmaceutical industry report similar metrics under 'Specialty Pharmaceuticals' or 'Biosimilars' segments, often highlighting these as higher-margin alternatives to traditional commodity generics.
vtrs_segment_complex_gx_and_biosimilars_sales_revenue_goods_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $332.80M | $332.00M | $348.40M | $390.80M | $354.80M | $320.20M | $247.60M | $136.10M | $139.20M | $174.40M |
| QoQ Change | — | -0.2% | +4.9% | +12.2% | -9.2% | -9.8% | -22.7% | -45.0% | +2.3% | +25.3% |
| YoY Change | — | — | — | — | +6.6% | -3.6% | -28.9% | -65.2% | -60.8% | -45.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's complex gx and biosimilars — sales revenue, goods, net?
- Viatris (VTRS) reported complex gx and biosimilars — sales revenue, goods, net of $174.40M in Q3 2023.
- How has Viatris's complex gx and biosimilars — sales revenue, goods, net changed year-over-year?
- Viatris's complex gx and biosimilars — sales revenue, goods, net decreased by 45.5% year-over-year, from $320.20M to $174.40M.
- What does complex gx and biosimilars — sales revenue, goods, net mean?
- Net revenue earned from selling specialized generic drugs and biosimilars that are harder to manufacture than standard generics.